Stavudine

Generic Name
Stavudine
Brand Names
Zerit
Drug Type
Small Molecule
Chemical Formula
C10H12N2O4
CAS Number
3056-17-5
Unique Ingredient Identifier
BO9LE4QFZF
Background

A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

Indication

For the treatment of human immunovirus (HIV) infections.

Associated Conditions
Human Immunodeficiency Virus (HIV) Infections
Associated Therapies
-

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Phase 2
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
80
Registration Number
NCT00002241
Locations
🇺🇸

Chelsea Village Med Ctr, New York, New York, United States

🇺🇸

St Lukes / Roosevelt Hosp / HIV Center, New York, New York, United States

🇺🇸

Univ of California at San Francisco Gen Hosp, San Francisco, California, United States

and more 15 locations

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Triangle Pharmaceuticals
Registration Number
NCT00002412
Locations
🇺🇸

Dr Robert Wallace, St. Petersburg, Florida, United States

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Phase 3
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
400
Registration Number
NCT00002208
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins Hosp, Baltimore, Maryland, United States

🇺🇸

Univ of Alabama at Birmingham, Birmingham, Alabama, United States

and more 12 locations

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Phase 3
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Triangle Pharmaceuticals
Registration Number
NCT00006208
Locations
🇺🇸

East Bay Clinical Trial Ctr, Concord, California, United States

🇺🇸

Orange Coast Med Group, Newport Beach, California, United States

🇺🇸

Health Positive, Safety Harbor, Florida, United States

and more 60 locations

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
100
Registration Number
NCT00002379
Locations
🇺🇸

Phoenix Body Positive, Phoenix, Arizona, United States

🇺🇸

Saint Vincent's AIDS Ctr, New York, New York, United States

🇺🇸

George Washington Med Ctr, Washington, District of Columbia, United States

and more 12 locations

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT00002381
Locations
🇺🇸

Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States

🇺🇸

Roger Williams Med Ctr, Providence, Rhode Island, United States

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Phase 4
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Target Recruit Count
230
Registration Number
NCT00005106
Locations
🇺🇸

Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States

🇺🇸

THE Clinic, Los Angeles, California, United States

🇺🇸

Maxine Liggins, Los Angeles, California, United States

and more 36 locations

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Registration Number
NCT00002442
Locations
🇺🇸

Southwest Infectious Disease Association / PA, Dallas, Texas, United States

🇺🇸

Univ TX Galveston Med Branch, Galveston, Texas, United States

🇺🇸

St Lukes - Roosevelt Hosp Ctr, New York, New York, United States

and more 9 locations

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Phase 4
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Agouron Pharmaceuticals
Target Recruit Count
200
Registration Number
NCT00005000
Locations
🇺🇸

Agouron Pharmaceuticals Inc, San Diego, California, United States

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Weill Medical College of Cornell University
Registration Number
NCT00002407
Locations
🇺🇸

Cornell AIDS Clinical Trials Unit, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath